"Ursodeoxycholic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
| Descriptor ID |
D014580
|
| MeSH Number(s) |
D04.210.500.105.225.272.962 D04.210.500.221.430.342.925
|
| Concept/Terms |
Ursodeoxycholic Acid- Ursodeoxycholic Acid
- Acid, Ursodeoxycholic
- Ursacholic Acid
- Acid, Ursacholic
- 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid
- 3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid
- Ursodiol
- Deoxyursocholic Acid
- Acid, Deoxyursocholic
|
Below are MeSH descriptors whose meaning is more general than "Ursodeoxycholic Acid".
Below are MeSH descriptors whose meaning is more specific than "Ursodeoxycholic Acid".
This graph shows the total number of publications written about "Ursodeoxycholic Acid" by people in this website by year, and whether "Ursodeoxycholic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1995 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ursodeoxycholic Acid" by people in Profiles.
-
Autoimmune Liver Diseases in Children. Pediatr Ann. 2018 Nov 01; 47(11):e452-e457.
-
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol. 2015 Oct; 63(4):952-61.
-
Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Dig Dis Sci. 2014 Nov; 59(11):2831-5.
-
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2014 Jul; 24(3):353-65.
-
Effects of ursodeoxycholic acid in esophageal motility and the role of the mucosa. An experimental study. Dis Esophagus. 2011 May; 24(4):291-4.
-
Ursodeoxycholic acid and chemoprevention of colorectal cancer. Gastroenterol Clin Biol. 2010 Oct; 34(10):516-22.
-
Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer. 2008; 60(3):389-400.
-
Primary biliary cirrhosis. Ann Hepatol. 2006 Jul-Sep; 5(3):198-200.
-
The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005 Nov 01; 22(9):783-8.
-
Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res. 2003 Jul 01; 63(13):3517-23.